TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3737692

Group type: EXPERIMENTAL
Intervention: Experimental Group (manipulation of the sacroiliac joint + moist heat + passive stretching)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (moist heat + passive stretching)
Number of subjects: 20
Study: 30138355

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 26585044

Group type: EXPERIMENTAL
Intervention: 3-session telephone brief motivational intervention on alcohol, delivered by a counselor trained in motivational interviewing during 6 weeks
Number of subjects: 730

Group type: COMPARATOR
Intervention: Control intervention of a scripted home fire and burn safety education delivered in 3 calls
Number of subjects: 730
Study: 24885915

Group type: EXPERIMENTAL
Intervention: Pain self-management course plus standard care
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 88
Study: 22260338

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion (PLF) with posterior instrumentation (group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF) with posterior instrumentation (group II)
Number of subjects: 80
Study: 20630640

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of Twinrix (720 ELISA units of inactivated hepatitis A virus and 20 μg of purified hepatitis B virus surface antigen) and Engerix-B (20 μg) at 0, 1, and 6 months plus Engerix-B, 40 μg, at month 2
Number of subjects: 96

Group type: COMPARATOR
Intervention: Engerix-B, 40 μg, at 0, 1, 2, and 6 months (control arm)
Number of subjects: 96
Study: 17118102

Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 15574076

Group type: EXPERIMENTAL
Intervention: Amino acid mixture (1 g per 10 kg of body weight) for a period of 1 month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for the same duration (control group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Additional control group (20 subjects not engaged in physical training)
Number of subjects: 60
Study: 11354523

Group type: EXPERIMENTAL
Intervention: Interval training A (90-80% vVO2 max)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval training B (100-70% vVO2 max)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interval training C (60 x 110% vVO2 max)
Number of subjects: 0
Study: 9143733

Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity (LOH)
Number of subjects: 21
Study: 7907348

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of ranitidine (6.25 mg/hr)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intermittent intravenous infusions of famotidine (20 mg every 12 hours)
Number of subjects: 18
Study: 3316059

Group type: EXPERIMENTAL
Intervention: BAY o 1248 (20 mg with breakfast)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: BAY m 1099 (50 mg with breakfast and dinner)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 7
Study: 29511011

Group type: EXPERIMENTAL
Intervention: Hazardous drinking (measured by AUDIT‐C)
Number of subjects: 871

Group type: COMPARATOR
Intervention: Control group (non-hazardous drinkers)
Number of subjects: 871
Study: 26873537

Group type: EXPERIMENTAL
Intervention: Therapeutic ERCP in patients ≥80 years
Number of subjects: 624

Group type: COMPARATOR
Intervention: Therapeutic ERCP in patients <65 years
Number of subjects: 624
Study: 25464679

Group type: EXPERIMENTAL
Intervention: Yoga training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical exercise (PE) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detraining after yoga training
Number of subjects: 0
Study: 22727870

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (matched children prior to treatment)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Age-matched normograms
Number of subjects: 55
Study: 20706875

Group type: COMPARATOR
Intervention: Placebo adherence (≥75% of prescribed study medication)
Number of subjects: 0
Study: 18706159

Group type: EXPERIMENTAL
Intervention: Pulmonary surfactants (PS) combined with continuous distending pressure (CDP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pulmonary surfactants (PS) alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Continuous distending pressure (CDP) alone
Number of subjects: 90
Study: 15919462

Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB) induction and daily mycophenolate mofetil (MMF; 2 g) with steroids (20 mg prednisone)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard triple therapy with tacrolimus, MMF, and prednisone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB) treatment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall rate of immediate function
Number of subjects: 51
Study: 15215814

Group type: EXPERIMENTAL
Intervention: Zofenopril (15 to 30 mg/d; n = 48)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enalapril (20 mg/d; n = 48)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both ACE inhibitors
Number of subjects: 96
Study: 11770424

Group type: EXPERIMENTAL
Intervention: Pasinizid (group A)
Number of subjects: 115

Group type: COMPARATOR
Intervention: HP regimen (group B1)
Number of subjects: 115

Group type: COMPARATOR
Intervention: SH regimen (group B2)
Number of subjects: 115
Study: 9441266

Group type: EXPERIMENTAL
Intervention: Parenteral antibiotic + oral ciprofloxacin sequential therapy (group B)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Parenteral antibiotics only (group A)
Number of subjects: 298
Study: 8356584

Group type: EXPERIMENTAL
Intervention: CsA high dose
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: CsA medium dose
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: CsA low dose
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Acute rejection episodes
Number of subjects: 1347
Study: 3621768

Group type: EXPERIMENTAL
Intervention: Quinaglute 324mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biquin Durules 250mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quinidex 300mg
Number of subjects: 12
Study: 31691981

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 0
Study: 29882279

Group type: EXPERIMENTAL
Intervention: R-THP-COP
Number of subjects: 81

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 81
Study: 29154068

Group type: EXPERIMENTAL
Intervention: Yoga home-exercise (10min daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Relaxation exercises only (control group)
Number of subjects: 38
Study: 26193126

Group type: EXPERIMENTAL
Intervention: Early ART (immediate ART initiation)
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Isoniazid Preventive Therapy (IPT)
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Deferred ART (ART initiation according to WHO criteria)
Number of subjects: 2056

Group type: COMPARATOR
Intervention: No IPT
Number of subjects: 2056
Study: 23866782

Group type: EXPERIMENTAL
Intervention: Surgical extraction during the middle of the menstrual cycle
Number of subjects: 145

Group type: COMPARATOR
Intervention: Surgical extraction during the menstrual period
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) users
Number of subjects: 145

Group type: COMPARATOR
Intervention: Nonusers of oral contraceptives
Number of subjects: 145
Study: 21944048

Group type: EXPERIMENTAL
Intervention: 3D-CT volumetry after 14 days of neoadjuvant chemoradiotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Histopathological response
Number of subjects: 39
Study: 18491582

Group type: EXPERIMENTAL
Intervention: Lisinopril monotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Amlodipine monotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of Lisinopril and Amlodipine
Number of subjects: 42
Study: 17699287

Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 206
Study: 14575344

Group type: EXPERIMENTAL
Intervention: Phonology first condition (12-week phonological intervention followed by 12 weeks of morphosyntax)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Morphosyntax first condition (12-week morphosyntax intervention followed by 12 weeks of phonology)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Alternating condition (phonology and morphosyntax goals alternating weekly)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Simultaneous condition (phonological and morphosyntactic goals each session)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 47
Study: 11221291

Group type: EXPERIMENTAL
Intervention: Barnidipine (10 or 20 mg/day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Barnidipine (20 mg/day)
Number of subjects: 106
Study: 8706770

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 1.0 mg b.i.d. for 3.5 days (seven doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 0.8 mg b.i.d. for 3.5 days (seven doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18415635

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion at a dose of 1.5 mg/kg body weight (over 10 min) 30 min before surgery, followed by 2 mg/kg body weight per h over 6 h and 0.5 mg/kg body weight per h for another 18 h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received identical volumes of 0.9% NaCl solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 40
Study: 3931273

Group type: EXPERIMENTAL
Intervention: MAA (Modified Amino Acid formulas)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard amino acids
Number of subjects: 18
Study: 31924249

Group type: EXPERIMENTAL
Intervention: Standardized SMAs led by a health educator with a set order of TTIM topics
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Patient-driven SMAs delivered collaboratively by a multidisciplinary care team
Number of subjects: 1440
Study: 30559105

Group type: COMPARATOR
Intervention: Molidustat (25, 50, and 75 mg once daily; 25 and 50 mg twice daily)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Molidustat (variable doses after switching from darbepoetin)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Molidustat (75 and 150 mg after switching from epoetin)
Number of subjects: 444
Study: 27183299

Group type: EXPERIMENTAL
Intervention: MPH XR-ODT (optimized dose)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 25838249

Group type: EXPERIMENTAL
Intervention: Varenicline with behavioral counseling
Number of subjects: 187

Group type: COMPARATOR
Intervention: Unassisted MILD patient
Number of subjects: 187
Study: 23685743

Group type: EXPERIMENTAL
Intervention: Early cardiac computed tomographic angiography (CCTA)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard emergency department evaluation
Number of subjects: 1000
Study: 21131223

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) and (40 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 19187079

Group type: EXPERIMENTAL
Intervention: Idraparinux 2.5 mg once-weekly subcutaneously
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Idraparinux 1.5 mg for patients with severe renal insufficiency
Number of subjects: 2064
Study: 17105798

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) - 150 mg of testosterone enanthate intramuscularly every 2 weeks for 6 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo - matching placebo intramuscularly every 2 weeks for 6 months
Number of subjects: 44
Study: 15507054

Group type: EXPERIMENTAL
Intervention: Person-centered showering
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Towel bath
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 73
Study: 11702050

Group type: EXPERIMENTAL
Intervention: Reference tissue‐based linear least squares (RLS) analysis using [(11)C]MP4A PET data.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nonlinear least squares (NLS) analysis using [(11)C]MP4A PET data.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Shape analysis (another method of [(11)C]MP4A kinetic analysis without blood sampling).
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference tissue‐based linear least squares (RLS) analysis.
Number of subjects: 38
Study: 9393520

Group type: EXPERIMENTAL
Intervention: Hydrodynamic rheolytic thrombectomy device
Number of subjects: 50
Study: 7951476

Group type: EXPERIMENTAL
Intervention: Smoking four 0.8 mg nicotine cigarettes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Consumption of 200 mg of caffeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Smoking four 0.8 mg cigarettes and ingesting 200 mg of caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 200 mg of caffeine (in non-smoking controls)
Number of subjects: 10
Study: 2889518

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg bid
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 30635862

Group type: EXPERIMENTAL
Intervention: Linkage to care (attended a clinic)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Initiation of ART within 3 months
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Linkage to care associated with HIV-status disclosure intentions
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Linkage to care associated with treatment readiness
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Linkage to care negatively associated with good health
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Linkage to care negatively associated with weekly alcohol consumption
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Linkage to care negatively associated with internalised stigma
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Perceived stigma
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Barriers to ART initiation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Motivating factors for ART initiation
Number of subjects: 86
Study: 26559709

Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI)
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 1487

Group type: COMPARATOR
Intervention: Control (usual programs)
Number of subjects: 1487
Study: 25385166

Group type: EXPERIMENTAL
Intervention: Supervised core strengthening programme
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Home-based core strengthening programme
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 24379274

Group type: COMPARATOR
Intervention: Chronic ambulatory peritoneal dialysis (CAPD) patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Peritoneally dialyzed (PD) patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Patients with hyperglycemia
Number of subjects: 25
Study: 21865768

Group type: EXPERIMENTAL
Intervention: Sodium glycerophosphate in TPN emulsion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pure sodium glycerophosphate formulation (reference)
Number of subjects: 10
Study: 19624359

Group type: EXPERIMENTAL
Intervention: PediSedate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 36
Study: 16750984

Group type: EXPERIMENTAL
Intervention: Subjects with asthma
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Subjects without asthma from index families
Number of subjects: 2208

Group type: COMPARATOR
Intervention: General population controls
Number of subjects: 2208
Study: 15570289

Group type: EXPERIMENTAL
Intervention: Bone resorption markers (BRM)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: C-terminal telopeptide of collagen I
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Bone formation markers (BFM)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Ratios BRM/BFM containing bAP
Number of subjects: 176
Study: 12767950

Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 9553645

Group type: COMPARATOR
Intervention: Heparin/Aspirin (H/A) alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Heparin/Aspirin in combination with IVIg
Number of subjects: 82
Study: 9055693

Group type: EXPERIMENTAL
Intervention: Tetracycline solution conditioning for 5 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sterile saline solution rinse
Number of subjects: 10
Study: 2244558

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 359904

Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 0.25% and 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pilocarpine 1%, 2%, and 4%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Timolol alone or in combination with a topical cholinergic agent or/and a systemic carbonic anhydrase inhibitor
Number of subjects: 40
Study: 30758163

Group type: EXPERIMENTAL
Intervention: RAMP Test (0.27 W·sec⁻¹)
Number of subjects: 57

Group type: COMPARATOR
Intervention: STEP Test (50W·3min⁻¹)
Number of subjects: 57
Study: 28917374

Group type: EXPERIMENTAL
Intervention: Bell pepper juice (100 ml, twice/day) with integrated approach of yoga therapy (IAYT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Integrated approach of yoga therapy (IAYT)
Number of subjects: 50
Study: 26686275

Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine and Performance pressure
Number of subjects: 0
Study: 24482441

Group type: EXPERIMENTAL
Intervention: Micronutrients (n = 42)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 80
Study: 21953572

Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg single dose) in subjects with normal renal function
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg single dose) in subjects with severe renal impairment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg single dose) in subjects receiving hemodialysis
Number of subjects: 16
Study: 19025719

Group type: EXPERIMENTAL
Intervention: Oil diet (vegetables low in beta-carotene with supplemental beta-carotene in salad dressing oil)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mixed diet (vegetables and fruits high in beta-carotene)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison between oil diet and mixed diet
Number of subjects: 24
Study: 17563408

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (10mg/d)
Number of subjects: 35
Study: 15217929

Group type: EXPERIMENTAL
Intervention: Higher serum IGF-I levels
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Higher serum IGFBP-3 levels
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Lower serum IGFBP-3 levels
Number of subjects: 253

Group type: COMPARATOR
Intervention: Lower IGF-I levels
Number of subjects: 253

Group type: COMPARATOR
Intervention: Lower IGFBP-3 levels
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Higher IGF-I levels
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Higher IGFBP-3 levels
Number of subjects: 253
Study: 11738689

Group type: EXPERIMENTAL
Intervention: Nasal spray containing alpha-haemolytic streptococci (AHS), administered once daily for 4 months.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo nasal spray, administered once daily for 4 months.
Number of subjects: 43
Study: 9718538

Group type: EXPERIMENTAL
Intervention: Exercise program (40 minutes of jogging and 20 minutes of gymnastics three times a week for 1 year)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Exercise program (40 minutes of jogging and 20 minutes of gymnastics three times a week for 6 months)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Exercise program (after 6 months, introduced to exercise classes with wrist weights of 0.8 kg on each arm)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Exercise program (after 6 months)
Number of subjects: 83
Study: 7664364

Group type: EXPERIMENTAL
Intervention: New method using a guide wire for endotracheal tube replacement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Old method of changing endotracheal tubes
Number of subjects: 16
Study: 29784554

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600mg pre-event
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (pre-event to post-event)
Number of subjects: 40
Study: 27456464

Group type: EXPERIMENTAL
Intervention: Colla corii asini (CCA) 15 g
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 72
Study: 24981506

Group type: EXPERIMENTAL
Intervention: Adjuvant whole brain radiotherapy (WBRT) following local treatment of intracranial melanoma metastases
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pilot study accrual
Number of subjects: 54
Study: 23053340

Group type: EXPERIMENTAL
Intervention: MicroPulse (MP) treatment at the active leakage site guided by fluorescein angiography (n=16 eyes)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg Bevacizumab (BCZ) (n=10 eyes)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Passive observation (Control group) (n=26 eyes)
Number of subjects: 52
Study: 19775677

Group type: EXPERIMENTAL
Intervention: Social problem-solving strategies
Number of subjects: 439
Study: 18344099

Group type: EXPERIMENTAL
Intervention: Oral administration of fomepizole (15 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous administration of fomepizole (15 mg/kg)
Number of subjects: 10